Condition: BRCA1/2 · Geneitic Testing · Sponsor: Memorial Sloan Kettering Cancer Center
The purpose of this study is to learn how people with BRCA1/2 mutations respond to genetic risk modifier testing. The researchers will learn more about how people make choices about their health care, including about methods to screen for prostate cancer. Researchers are also doing this study to learn about how the genetic risk modifier test affects people's thoughts and feelings.
This description comes directly from the study's public registry record.
Jada Hamiliton, PhD, MPH · 646-888-0049 · hamiltoj@mskcc.org
Kenneth Offit, MD · 646-888-4050
Always discuss trial participation with your own doctor first.
| Memorial Sloan Kettering Cancer Center | New York, New York, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07197723